Real‐life experience with disease‐modifying drugs in hereditary transthyretin amyloid polyneuropathy: A clinical and electrophysiological appraisal
Overall effectiveness of ATTRv-PN treatments in routine care is good. However, individual assessments show up to 40% deterioration over time. Electrophysiological measures are valuable monitoring tools but are not more sensitive to change than clinical scores. Results must be confirmed in larger cohorts.
Authors
- Annie Verschueren (ORCID: https://orcid.org/0000-0003-1266-9062)
- Aude‐Marie Grapperon (ORCID: https://orcid.org/0000-0002-4196-9374)
- Étienne Fortanier (ORCID: https://orcid.org/0000-0003-2797-9389)
- Emmanuelle Salort‐Campana (ORCID: https://orcid.org/0000-0002-1846-3017)
- Ludivine Kouton
- Émilien Delmont (ORCID: https://orcid.org/0000-0002-5591-2774)
- Shahram Attarian (ORCID: https://orcid.org/0000-0002-7211-4694)
- Hadia Rebouh
Institutions
- Aix-Marseille Université (FR)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1111/ene.16571
- Citations
- 2
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.47